Hodgkin’s disease: Further information derived from cell lines

  • H. Burrichter
  • M. Schaadt
  • C. Kortmann
  • W. Heit
  • E. Schell-Frederick
  • H. Stein
  • V. Diehl
Part of the Developments in Oncology book series (DION, volume 32)

Abstract

Histologically, Hodgkin’s disease (HD) is characterized by a striking cellular pleomorphism with a low percentage of Hodgkin (H) and Sternberg-Reed (SR) cells, which represent the tumor cell population, admixed with nonmalignant cells, e.g., polymorphonuclears, macrophages, B-cells and T-cells. Aneuploidy and clonal development of H and SR cells confirm their neoplastic nature. However, chromosome markers that are specific for HD have not been identified in freshly sampled tumors. The reasons for the presence of non-malignant cells surrounding H- and SR-cells are still unknown. This admixture has been regarded as a type of graft-vs-host reaction.

Keywords

Migration Agar Lymphoma Leukemia Agarose 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kaplan HS (1981). On the biology and immunology of Hodgkin’s disease. Hematology and Blood Transfusion 26: 11–23.Google Scholar
  2. 2.
    Reed DM (1902). On the pathological changes in Hodgkin’s disease with especial reference to its relation to tuberculosis. Johns Hopkins Hosp Rep 10: 133–196.Google Scholar
  3. 3.
    Twomey JJ and Rice L (1980). Impact of Hodgkin’s disease on the immune system. Semin Oncol 7: 114–125.PubMedGoogle Scholar
  4. 4.
    Kaplan HS (1980). Hodgkin’s disease: Unfolding concepts concerning its nature, management and prognosis. Cancer 45: 2439–2474.PubMedCrossRefGoogle Scholar
  5. 5.
    Fuks Z, Strober S, King DP and Kaplan HS (1976). Reversal of cell surface abnormalities of T-lymphocytes in Hodgkin’s disease after in vitro incubation in fetal sera. J Immunol 117: 1331–1335.PubMedGoogle Scholar
  6. 6.
    Goodwin JS, Messner RP, Bankhurst AD et al. (1977). Prostaglandin-producing suppressor cells in Hodgkin’s disease. N Engl J Med 297: 963–968.PubMedCrossRefGoogle Scholar
  7. 7.
    Bieber MM, King DP, Strober S and Kaplan HS (1979). Characterization of an E-rosette inhibitor ( ERI) in the serum of patients with Hodgkin’s disease, as a glycolipid. Clin Res 27: 081A.Google Scholar
  8. 8.
    Diehl V, Kirchner HH, Burrichter H et al. (1982). Characteristics of Hodgkin’s disease-derived cell lines. Cancer Treat Rep 66: 615–632.PubMedGoogle Scholar
  9. 9.
    Schaadt M, Diehl V, Stein H et al. (1980). Two neoplastic cell lines with unique features derived from Hodgkin’s disease. Int J Cancer 26: 723–731.PubMedCrossRefGoogle Scholar
  10. 10.
    Bradley TR and Metcalf D (1966). The growth of mouse bone marrow cells in vitro. Austr J Exp Biol Sci 44: 287–300.CrossRefGoogle Scholar
  11. 11.
    Heit W, Rich IN and Kubanek B (1981). Macrophage-dependent production of erythropoietin and colony-stimulating factor. Hematology and Blood Transfusion 27: 73–78.Google Scholar
  12. 12.
    Kortmann C, Burrichter H, Monner D et al. (1984). Interleukin-1-like activity constitutively generated by Hodgkin derived cell lines. L. Measurement in a human lymphocyte co-stimulator assay. Immunobiology 166: 318–333.Google Scholar
  13. 13.
    Schaadt M, Diehl V, Kalden JR et al. (1978). Langzeitauswirkungen der Splenektomie auf den immunstatus von Hodgkin-Patienten in Abhängigkeit von der Therapieform. Med Klinik 73: 1381–1386.Google Scholar
  14. 14.
    Jondal M, Holm G and Wigzell H (1972). Surface markers on human T- and B-lymphocytes. J Exp Med 136: 207–215.PubMedCrossRefGoogle Scholar
  15. 15.
    Nelson RD, McCormack RT and Fiegel VD (1978). Chemotaxis of human leucocytes under agarose. In: Gallin JI and Quie PG (Eds.) Leukocyte Chemotaxis, pp 25–42.Google Scholar
  16. 16.
    Oppenheim JJ, Stadler BM, Siraganian RP et al. (1982). Lymphokines: Their role in lymphocyte responses. Properties of interleukin 1 Fed Proc 41: 257–262.Google Scholar
  17. 17.
    Burrichter H, Heit W, Schaadt M et al. (1983). Production of colony-stimulating factors by Hodgkin cell lines. Int J Cancer 31: 269–274.PubMedCrossRefGoogle Scholar
  18. 18.
    Farrar JJ and Hilfiker ML (1982). Antigen-nonspecific helper factors in the antibody res-pose. Fed Proc 41: 263–268.PubMedGoogle Scholar
  19. 19.
    Murphy PA, Simon PL and Willoughby WF (1980). Endogenous pyrogens made by rabbit peritoneal exudate cells are identical with lymphocyte-activating factors made by rabbit alveolar macrophages. J Immunol 124: 2498–2501.PubMedGoogle Scholar
  20. 20.
    Ruehl H, Enders B, Bur M and Sieber G (1981). Impaired B-lymphocyte reactivity in patients with Hodgkin’s disease and non-Hodgkin’s lymphomas. Blut 42: 271.CrossRefGoogle Scholar
  21. 21.
    Ford RJ, Mehta S, Davis F and Maizel A (1982). Growth factors in Hodgkin’s disease. Cancer Treat Rep 66: 633–638.PubMedGoogle Scholar
  22. 22.
    Newcom SR and O’Rourke L (1982). Potentiation of fibroblast growth by nodular sclerosing Hodgkin’s disease cell cultures. Blood 60: 228–237.PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1985

Authors and Affiliations

  • H. Burrichter
    • 1
  • M. Schaadt
    • 1
  • C. Kortmann
    • 2
  • W. Heit
    • 3
  • E. Schell-Frederick
    • 1
  • H. Stein
    • 4
  • V. Diehl
    • 1
  1. 1.Medizinische Universitätsklinik IKölnGermany
  2. 2.Medizinische Hochschule HannoverGermany
  3. 3.UniversitätsklinikUlmGermany
  4. 4.Nuffield Department of PathologyOxfordUK

Personalised recommendations